Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab.
about
Ocular Complications of Diabetes and Therapeutic ApproachesLong-term delivery of protein therapeuticsOcular delivery of macromoleculesNanoengineering of therapeutics for retinal vascular disease.GS/DBM/PLA porous composite biomaterial for the treatment of infective femoral condyle defect in ratsDiabetic Retinopathy: Battling the Global Epidemic.Drug and gene delivery to the back of the eye: from bench to bedside.Intravitreal drug delivery in retinal disease: are we out of our depth?Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics.Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications.Recent perspectives on the delivery of biologics to back of the eye.Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.Drug delivery to the eye: what benefits do nanocarriers offer?A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles.Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab.Ocular delivery of proteins and peptides: challenges and novel formulation approaches.How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.Controlled and sustained release of pharmaceuticals via single step solvent-free encapsulation.Therapeutic Potential of Inorganic Nanoparticles for the Delivery of Monoclonal Antibodies
P2860
Q26749412-B04747BD-DE14-421A-BEDC-73901A4C3FCBQ26860505-15359E1F-6BB8-4362-BDC8-BEDC2D325ACFQ34079676-AF49E8DD-3154-4F32-A0B6-E749FF763651Q35645705-76319F80-2E07-44C2-92C3-B5ADB6E09D40Q36953292-B70FFB9D-AB34-4ED1-808C-5940B2D7923BQ37494858-ECE08465-A60D-42CE-B335-43B1B667F3B1Q37731899-027F6AD2-F893-4D2D-B304-470C11CF49BDQ38220453-EEDE7E03-97CB-4226-B377-2B193A559A46Q38368715-0F0B4812-209B-46FC-9446-2CDE86DF3487Q38655920-400427EC-6D3B-4A6F-90A7-099552AD7E2BQ38940171-CFE3B02C-7AFA-4D38-AEDE-9EEF5F6A06F7Q38987118-F38E7FFB-9245-43D1-868D-B65C023FD1E8Q39130097-13F5C854-E24B-4EC8-836A-AF355A764BDAQ42198535-5D042CCC-1C5B-41F0-8F49-54937AAA2497Q47156996-0572C016-518A-4D5E-A186-DE1C1D6511E4Q47729137-F68A71E0-60A4-4418-BBC5-EB02FD40AF47Q48902538-2D0D2243-9F1F-4F91-A63E-8CAB914ED73FQ53357988-1E99E74E-70A5-43E1-8E91-45DA520EF0AEQ59113319-DA18CB39-5015-438A-8B0B-2F37776602D7
P2860
Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Nanoparticles in porous microp ...... ained delivery of bevacizumab.
@en
Nanoparticles in porous microp ...... ained delivery of bevacizumab.
@nl
type
label
Nanoparticles in porous microp ...... ained delivery of bevacizumab.
@en
Nanoparticles in porous microp ...... ained delivery of bevacizumab.
@nl
prefLabel
Nanoparticles in porous microp ...... ained delivery of bevacizumab.
@en
Nanoparticles in porous microp ...... ained delivery of bevacizumab.
@nl
P2093
P2860
P356
P1476
Nanoparticles in porous microp ...... ained delivery of bevacizumab.
@en
P2093
Arun K Upadhyay
J Mark Petrash
Sarath K Yandrapu
Uday B Kompella
P2860
P304
P356
10.1021/MP400487F
P407
P577
2013-11-12T00:00:00Z